Do Beta-blockers Affect the Use of Beta-agonist Inhalers in COPD?
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Incremental Shuttle Walk Test Result after taking beta-blockers
研究概览
简要总结
Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out. The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients. This study will investigate what happens to the airways of people taking both of these drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 100 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of COPD
- •> 40 years of age
- •> 15 pack year smoking history
排除标准
- •Contra-indication to beta-blocker use
- •Severe COPD FEV1 < 30% or 1 L
- •Not responsive the methacholine
研究组 & 干预措施
R302
Daily placebo capsules
干预措施: bronchodilator response (Drug)
R303
Daily metoprolol 95mg capsules
干预措施: bronchodilator response (Drug)
R304
Daily propranolol 80mg capsules
干预措施: bronchodilator response (Drug)
Open Label
Daily Metoprolol 190mg capsules
干预措施: bronchodilator response (Drug)
结局指标
主要结局
Incremental Shuttle Walk Test Result after taking beta-blockers
时间窗: 7-10 days
Bronchodilator response to salbutamol after beta-blockers
时间窗: 7-10 days
次要结局
未报告次要终点
